Clinical trials in Boadilla Del Monte – page 104

3 267 clinical trials in Boadilla Del Monte, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Boadilla Del Monte at a glance

3 267

clinical trials

Research sites1

Quick filters

3 267 trials in Boadilla Del Monte

Open in trial search

Conjunctivitis allergic+2

Not yet recruiting

Efficacy and safety of allergenic extract of Olea europaea pollen polymerized with glutaraldehyde in patients with olive pollen allergy, including mild‑to‑moderate asthma

Investigational

Efficacy and safety of allergenic extract of Olea europaea pollen polymerized with glutaraldehyde in patients with olive pollen allergy, including mild‑to‑moderate asthma

Investigational

Spain

Participants:0–17 years · 18–64 years
Sponsor:Inmunotek S.L.

Contact Research Centre

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ziloretgene parvec
Sponsor:Atsena Therapeutics Inc.

Contact Research Centre

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:DNTH103
Sponsor:Dianthus Therapeutics Inc.

Contact Research Centre

Ovarian cancer

Not yet recruiting

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Contact Research Centre

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Clear cell papillary renal cell carcinoma

Not yet recruiting

Study of Sacituzumab Tirumotecan in Patients with Papillary Renal Cell Carcinoma and Variant Histology Urothelial Carcinoma (Rare Genitourinary Tumors)

InvestigationalNo placebo

Study of Sacituzumab Tirumotecan in Patients with Papillary Renal Cell Carcinoma and Variant Histology Urothelial Carcinoma (Rare Genitourinary Tumors)

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Sacituzumab Tirumotecan
Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Contact Research Centre

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational

Spain

Participants:0–17 years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:GSK5733584
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Osteosarcoma+2

Not yet recruiting

A Randomized Study of Trabectedin With Low‑Dose Radiotherapy Versus Trabectedin Alone in Adults With Advanced Soft Tissue Sarcoma, Osteosarcoma, or Ewing Sarcoma

Registered drugNo placebo

A Randomized Study of Trabectedin With Low‑Dose Radiotherapy Versus Trabectedin Alone in Adults With Advanced Soft Tissue Sarcoma, Osteosarcoma, or Ewing Sarcoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trabectedin
Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Contact Research Centre

Group B streptococcus neonatal sepsis

Not yet recruiting

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational

Spain

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:GBS-NN
Sponsor:Minervax ApS

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Deupirfenidone
Sponsor:Puretech Lyt 100 Inc.

Contact Research Centre

Varicella+5

Not yet recruiting

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo

Spain

Participants:0–17 years · Healthy volunteers
Substances:GSKVX000000025896
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Boadilla Del Monte

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development and immune responses for multiple infectious diseases, including studies of combination vaccines for childhood diseases and COVID-19 boosters.

MMRV Vaccine Studies
COVID-19 Booster Research
RSV Prevention

Special emphasis on pediatric populations and vaccine co-administration safety protocols.

02 Oncology Research

Comprehensive studies on various cancer types, with focus on pediatric liver cancers and innovative treatment approaches for solid tumors.

Hepatoblastoma Treatment
High-Grade Glioma Therapy
Prostate Cancer Management

Integration of targeted therapies and combination treatment protocols.

03 Cardiovascular Medicine

Investigations into cardiovascular disease prevention and treatment, particularly focusing on post-heart attack care and preventive measures.

ASCVD Prevention
Acute Coronary Syndrome
Cardiovascular Risk Management

Emphasis on long-term cardiovascular outcomes and preventive strategies.

04 Women's Health

Studies examining reproductive health and related conditions, including contraceptive efficacy and treatments for gynecological infections.

Contraceptive Development
Vaginal Health Studies
Treatment of Candidiasis

Focus on innovative delivery systems and treatment options.

Back to Spain All countries